CSCIFOTCPerfumes, Cosmetics & Other Toilet PreparationsFiscal year ends December 31
COSCIENS Biopharma Inc.
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 20-F on Mar 25, 2026
$6.49+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $24.10M
- P/E (TTM)
- –
- Dividend yield
- –
COSCIENS Biopharma Inc. revenue by segment
By business segment
| Revenue | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | TTM Q2 23 | TTM Q1 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Active ingredient [member] | $7.04M | $7.67M | $7.91M | $7.82M | $8.49M | $7.31M | $7.56M | $6.62M | $7.14M | – | – | – | 93.9% | -17.1% |
| Pharmaceutical [member] | – | $1.38M | $1.54M | $1.21M | $1.10M | – | – | – | – | – | – | – | – | – |
| Biopharmaceutical [member] | – | – | – | – | $1.10M | – | – | – | – | – | – | – | – | – |
By product or service
| Revenue | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | TTM Q2 23 | TTM Q1 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| License fees [member] | – | – | – | – | – | – | – | – | – | $2.43M | $3.03M | $2.03M | – | – |
| Royalties [member] | – | – | – | – | – | – | – | – | – | $72.00K | $83.00K | $100.00K | – | – |
| Supply chain [member] | – | – | – | – | – | – | – | – | – | $95.00K | $134.00K | $129.00K | – | – |
| Development services [member] | – | – | – | – | – | – | – | – | – | $4.27M | $5.47M | $3.99M | – | – |
By region
From the segment and revenue-disaggregation notes of COSCIENS Biopharma's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.